Effect of N-Acetylcysteine on Neutrophil Lymphocyte Ratio And Length of Stay In COVID-19 Patients
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Neutrophil to lymphocyte ratio
研究概览
简要总结
This research is a study that compares the administration of N-acetylcysteine at various doses with the outcomes of COVID-19 patients, namely the neutrophil-to-lymphocyte ratio and length of stay.
详细描述
This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into four groups. The control group K0 received standard therapy without NAC, while the treatment group K1 received NAC injections of 1200mg/day, K2 NAC tablets 3x400mg/day, and K3 NAC tablets 3x200mg/day. Different tests using Way ANOVA and LSD or Kruskal-Wallis and Mann-Whitney.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
This study used N acetyl cysteine capsules and placebo, which were made similar in shape; researchers and patients did not know who was getting the drug or placebo.
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •moderate or severe grade confirmed COVID-19 (patients with symptoms and radiological examination showing pneumonia with or without signs of severe pneumonia: SpO2<90%, respiratory rate>30x/min, and severe respiratory distress) who were admitted to UNS Hospital and age 18-60 years old
排除标准
- •patients who died during the treatment period
研究组 & 干预措施
N-acetylcysteine pills 600 mg per day
N-acetylcysteine pills 600 mg per day orally
干预措施: N-acetyl cysteine (Drug)
N-acetylcysteine injection 1200 mg
N-acetylcysteine injection 1200 mg per day
干预措施: N-acetyl cysteine (Drug)
N-acetylcysteine pill 1200 mg
N-acetylcysteine pill 1200 mg orally per day
干预措施: N-acetyl cysteine (Drug)
placebo
Capsule with shape and appearance similar to N-acetylcysteine
干预措施: N-acetyl cysteine (Drug)
结局指标
主要结局
Neutrophil to lymphocyte ratio
时间窗: Change of Neutrophil to lymphocyte ratio at 7 day
Neutrophil to lymphocyte ratio
Length of stay
时间窗: From date of randomization until the date of return from hospital
Length of stay
次要结局
未报告次要终点
研究者
Nurhasan Agung Prabowo
Head of Hospital Research Unit
Universitas Sebelas Maret